Wednesday June 10, 2015

13:00-13:15	Opening session Cai Grau, Aarhus: Welcome to BiGART2015 and Aarhus. Practical information.
13:15-14:25	Session 1: Radiobiology of human tumors: guidance for therapy Chairs: Michael Horsman and Marianne Nordsmark
13:15-13:35	Keynote lecture Jan Bussink, Nijmegen: The tumor microenvironment in head and neck cancer: radiotherapy and EGFR
13:35-13:45	Proffered papers Christina Sæten Fjeldbo, Oslo: Construction of a prognostic hypoxia gene classifier in cervical cancer that is reflected in dynamic contrast-enhanced (DCE) MR images
13:45-13:55	Brita Singers Sørensen, Aarhus: Relative biological effectiveness for tumor control and acute skin damage in a mouse model
13:55-14:05	Ghazaleh Ghobadi, Amsterdam: Histopathology-derived modeling of prostate cancer tumor control probability: implications for the dose to the tumor and the gland
14:05-14:15	Thomas Wittenborn, Aarhus: Targeting the microenvironment and vasculature of tumours to improve response to radiation administered using a dose and schedule equivalent to that for a stereotactic treatment: the effect of hypoxic modifiers
14:15-14:25	Gregers Rasmussen, Copenhagen: Association between immunohistochemical and imaging biomarkers in head and neck squamous cell carcinomas
14:25-14:55	Coffee break and poster viewing
14:55-17:00	Session 2: Late normal tissue effects Chairs: Joe Deasy and Jan Alsner
	Keynote lectures
14:55-15:15	Klaus R. Trott, Münich: Radiation-induced secondary cancers
15:15-15:30	Nicolaj Andreassen, Aarhus: Recent activities and future plans of the In-
15:30-15:40	ternational Radiogenomics Consortium (RGC) Michael Baumann, Dresden: European radiotherapy treatment plan databank
15:40-15:50	Discussion

15:50-16:00	Proffered papers Azza Khalil, Aarhus: New dose constraint reduces radiation-induced pneumonitis in locally advanced NSCLC treated with Intensity-Modulated Radiotherapy	
16:00-16:10	Marciana N. Duma, Münich: Tangential field radiotherapy for breast cancer: the dose to the heart and heart subvolumes	
16:10-16:20	Laura Tuomikoski, Helsinki: Post-RT saliva production can be predicted by measuring pre-RT salivary function and mean glandular doses	
16:20-16:30	Line Schack, Aarhus: SNP analysis on late radiation induced toxicity analyzed by questionnaires and anal physiological methods in prostate cancer patients.	
16:30-16:40	Camilla Stokkevåg, Bergen: Risk of radiation-induced secondary rectal and bladder cancer following radiotherapy of prostate cancer	
16:40-16:50	Laura Rechner, Copenhagen: Risk-optimized proton therapy treatment planning to minimize second cancers after radiotherapy of the prostate	
16:50-17:00	Britta Weber, Aarhus: Long-term outcomes and toxicity after proton beam radiotherapy of large non-peripapillary choroidal melanoma	
17:15 17:30 19:45 20:30	Bus departure for New Moesgaard Museum Welcome reception – New Moesgaard Museum Busses return to Hotel Marselis Dinner at Hotel Marselis	
Thursday June 11, 2015		
	Thursday June 11, 2015	
8:00-10:00	Thursday June 11, 2015 Session 3: Recent developments in functional imaging Chairs: Eirik Malinen and Stine Korreman	
8:00-10:00 8:00-8:20	Session 3: Recent developments in functional imaging	
	Session 3: Recent developments in functional imaging Chairs: Eirik Malinen and Stine Korreman Keynote lectures Uulke van der Heide, Amsterdam: Recent developments in quantitative	
8:00-8:20	Session 3: Recent developments in functional imaging Chairs: Eirik Malinen and Stine Korreman Keynote lectures Uulke van der Heide, Amsterdam: Recent developments in quantitative imaging for radiotherapy. Karin Haustermans, Leuven: The role of functional imaging and molecular markers for organ-preserving strategies after chemo-radiotherapy for rectal cancer Proffered papers Niels Raaijmakers, Utrecht: Validation is crucial in head and neck transla-	
8:00-8:20 8:20-8:40	Session 3: Recent developments in functional imaging Chairs: Eirik Malinen and Stine Korreman Keynote lectures Uulke van der Heide, Amsterdam: Recent developments in quantitative imaging for radiotherapy. Karin Haustermans, Leuven: The role of functional imaging and molecular markers for organ-preserving strategies after chemo-radiotherapy for rectal cancer Proffered papers Niels Raaijmakers, Utrecht: Validation is crucial in head and neck translational imaging research Haley Clark, Vancouver: Preliminary findings using dynamic contrastenhanced magnetic resonance imaging to identify functional aspects within	
8:00-8:20 8:20-8:40 8:40-8:50	Session 3: Recent developments in functional imaging Chairs: Eirik Malinen and Stine Korreman Keynote lectures Uulke van der Heide, Amsterdam: Recent developments in quantitative imaging for radiotherapy. Karin Haustermans, Leuven: The role of functional imaging and molecular markers for organ-preserving strategies after chemo-radiotherapy for rectal cancer Proffered papers Niels Raaijmakers, Utrecht: Validation is crucial in head and neck translational imaging research Haley Clark, Vancouver: Preliminary findings using dynamic contrast-	

9:20-9:30	Joachim Chan, Wirral: Dose painting radiotherapy for high risk prostate cancer: delayed 18F-choline PET/CT imaging before neo-adjuvant hormone therapy improves detection rates
9:30-9:40	Endre Grøvik, Oslo: Feasibility of multi-echo dynamic MRI for simultaneous acquisition of T1-weighted and R2* contrast kinetics in rectal cancer
9:40-9:50	Katherina Farr, Aarhus: Perfusion SPECT imaging and radiation-induced injury in the lung after curative radiotherapy for NSCLC
9:50-10:00	Søren Møller, Copenhagen: Early changes in perfusion of glioblastoma during radio- and chemotherapy evaluated by T1*-dynamic contrast enhanced MRI
10:00-10:30	Coffee break and poster viewing
10:30-12:40	Session 4: Clinical results – hypoxia, dose painting and adaptive radio- therapy
	Chairs: Vincenzo Valentini and Jacob Lindegaard
	Keynote lectures
10:30-10:50	Daniel Zips, Tübingen: Hypoxia dose painting in head and neck cancer
10:50-11:10	Peter Hoskin, London: Hypoxia dose painting in prostate and cervix cancer
11:10-11:30	Ivan Vogelius, Copenhagen: FDG PET based dose painting in head and neck cancer
	Proffered papers
11:30-11:40	Marie Tvilum Petersen, Aarhus: The clinical implication of introducing adaptive radiotherapy in the treatment of lung cancer patients
11:40-11:50	Patrick Berkovic, Ghent: Adaptive radiotherapy for locally-advanced non-small cell lung cancer, can we predict when and for whom?
11:50-12:00	Anne Vestergaard, Aarhus: Acute gastro-intestinal morbidity in a Phase II trial of online adaptive radiotherapy for urinary bladder cancer.
12:00-12:10	Ralph Leijenaar, Maastricht: Early prediction of pathological response in rectal cancer patients using "PET Radiomics" with independent validation
12:10-12:20	Marianne Assenholt, Aarhus: Application of coverage probability treatment planning for lymph node boosting in locally advanced cervical cancer
12:20-12:30	Sara Thörnqvist, Bergen: Adaptive radiotherapy strategies for pelvic tumours – a review of clinical implementations
12:30-12:40	Hella Sand, Aalborg: Correlation between pretreatment FDG-PET biological target volume and location of T-site failure after definitive radiation therapy for head and neck cancers
12:40-13:40	Lunch break
13:40-14:50	Session 5: Novel concepts in design of clinical trials in radiotherapy Chairs: Philippe Maingon and Kari Tanderup

13:40-14:00	Keynote lectures Philippe Lambin, Maastricht: Novel concepts of clinical research in radia-
14:00-14:20	tion oncology: from clinical trials to rapid learning health care Joe Deasy, New York: Data driven radiobiological modeling of tumor control probability
14:20-14:30	Proffered papers Armin Lühr, Dresden: Individual benefit for advanced head and neck cancer patients in terms of NTCP differences from intensity-modulated proton therapy for complete or sequential boost treatment versus intensity-modulated photon therapy
14:30-14:40	Morten Høyer, Aarhus: Radiation dose to the gastro-intestinal tract and patient-reported symptom domains after prostate cancer radiotherapy
14:40-14:50	Timo Deist, Maastricht: Clinical routine data as a viable source for radiation-induced lung toxicity prediction models
14:50-15:20	Coffee break and poster viewing
15:20-16:30	Session 6: How to establish clinical evidence in particle therapy? Chair: Phillipe Lambin and Morten Høyer
	Keynote lecture Michael Baumann, Dresden: Particle therapy, networks and infrastructure
	Presentation by panelists (5 min each) Philippe Maingon, Lyon Richard Pötter, Vienna Thomas Björk-Eriksen, Uppsala Jean-Philippe Pignol, Rotterdam Cai Grau, Aarhus
	Discussion
16:30-18:00	Poster viewing, including poster discussion groups. Refreshments.
18:00-19:30	Sculpture by the Sea (on your own)
19:30	Conference dinner (Varna Mansion, next to Hotel Marselis)

Friday June 12, 2015

8:00-10:00	Session 7: Image-guidance for adaptive radiotherapy and proton therapy Chairs: Jan-Jakob Sonke and Ludvig Muren
8:00-8:20	Keynote lectures Jan Lagendijk, Utrecht: The MR linac system and its impact on the radio- therapy process
8:20-8:40	Parag Parikh, St. Louis: Online adaptive radiation therapy in the abdomen: The challenge of bowel
8:40-9:00 9:00-9:20	Joao Seco, Boston: Image-guidance for adaptive proton therapy Marta Peroni, Villigen: The adaptive challenge in proton therapy
9:20-9:30	Proffered papers Christopher Kurz, Munich: Comparing strategies for CBCT-based dose recalculation to foster adaptive IMRT and IMPT of head and neck cancer patients
9:30-9:40	Lucas Persoon, Maastricht: Is integrated transit planar EPID dosimetry able to detect geometric changes in lung cancer patients treated with volumetric modulated arc therapy (VMAT)
9:40-9:50	Andreas Gravgaard Andersen, Aarhus: A method to evaluate the robust- ness of single beam proton plans for pelvic lymph node irradiation with re- spect to inter-fractional motion
9:50-10:00	Per Poulsen, Aarhus: Calculation of interplay effects caused by liver tumor motion during scanning proton therapy in a commercial treatment planning system
10:00-10:20	Coffee break (please remember to take down your poster)
10:20-11:50	Session 8: Radiotherapy in Europe 2020 Chairs: Michael Bauman and Jens Overgaard
10:20-10:30	Jens Overgaard, Aarhus: Introduction
10:30-10:50	Keynote lectures Josep M Borras, Barcelona: The need for radiotherapy in Europe 2020: Not only data but also a cancer plan
10:50-11:10 11:10-11:30 11:30-11:50	Christoffer Johansen, Copenhagen: Patient-reported outcome measures Vincenzo Valentini, Rome: Can automation reduce costs? Yolande Lievens, Ghent: Cost calculation: a necessary step on the winding road towards widespread adoption of advanced radiotherapy technology
	Discussion
11:50-12:00	Ludvig Muren: Closing of the meeting